Small Pharmaceuticals
Market Cap
₹36,586 ₹36,586 Cr.
P/E
89.45
PEG
1.96
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- Bull case hinges on securing a tier-1 out-licensing partner for Zaynich that accelerates US/EU penetration and adds upfront milestones, while bear case materializes if FDA issues a Complete Response Letter delaying launch beyond FY29.- The mix shift from generics (56% of FY26) to innovative NCEs (41% by FY31) is the central growth engine, with each delay in NCE commercialization directly compressing revenue and margin expansion.
- Biotech capacity doubling to capture the disposable insulin vacuum left by Novo Nordisk provides a secondary growth leg, but pricing pressure from entrenched players could cap gains.

Key Ratios

Debt to Equity
Debt to Equity
0.43
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
19.47 %
Institutions
Institutions
16.47 %
Market cap
Market cap
36,586 Cr
No. of Shareholders
No. of Shareholders
1.67 L
OPM (%)
OPM (%)
21.66 %
PE
PE
89.45
Prom Holding
Prom Holding
49.08 %
ROCE (%)
ROCE (%)
8.23
ROE (%)
ROE (%)
4.31
Sales
Sales
3,564 Cr
  • Wockhardt
  • Ajanta Pharma
  • Gland Pharma
  • TJI Pharma - Small Cap
Last updated on
      Price Range

      See where the stock is trading versus its 52-week high and low.

      Low
      1087
      52W Range
      High
      2422
      Timeline

      Key company specific updates.

      Custom financial statement

      Edit rows

      Forensics

      10 Yes

      Positive for this company

      2 Neutral

      Neutral for this company

      5 No

      Negative for this company

      0 No Data

      Insufficient data to analyse

      Market Share

      0.69 %
      (as of Jul 22)
      Anti - Diabetes - Market Share
      0.05 %
      (as of Jul 22)
      Anti-Infectives - Market Share
      0.01 %
      (as of Aug 20)
      Anti-Malarial - Market Share
      0.05 %
      (as of Nov 21)
      Antineo Plastic - Market Share
      4.31 %
      (as of Nov 21)
      Blood Related - Market Share
      0 %
      (as of Jul 22)
      Cardiovascular - Market Share

      Revenue mix

      Product Wise Break-Up

      Location Wise Break-Up

      Asset Break-Up

      Operational Metrics

        Select a Metric
        • Domestic Sales Growth - YoY (%)
        • R&D as a % of Total Sales (%)

        Peer Comparison

        Brands

        Spasmo Proxyvon

        Corporate Actions

        Consolidated
        DATE
        DETAILS
        Show More
        Show Less
        Show More
        Show Less

        Suppliers

        • Shaily Engineering Plastics Ltd.
        • Borosil Renewables Ltd.
        • Responsive Industries Ltd.
        • Hindusthan National Glass & Industries Ltd.
        • Vivimed Labs Ltd.

        FAQs on Wockhardt Ltd. Business

        Wockhardt Limited is a prominent Indian pharmaceutical and biotechnology company that prioritizes accessibility to high-quality medicines. They are active in Pharmaceuticals, Biotechnology, and Super Speciality Hospitals.

        Wockhardt major competitors are Ajanta Pharma, Ipca Laboratories, Glaxosmithkline Phar, Gland Pharma, Caplin Point Labs., Pfizer, Eris Lifesciences.
        Market Cap of Wockhardt is ₹36,125 Crs.
        While the median market cap of its peers are ₹44,778 Crs.

        Wockhardt seems to be less financially stable compared to its competitors.
        Altman Z score of Wockhardt is 8.37 and is ranked 7 out of its 8 competitors.

        Company Filing

        Discussions & Analysis

        Ideas Dashboard
        Results
        Timeline
        Watchlist
        Portfolio
        Alerts
        Stock Screener
        Market
        Raw Material